ARV-393

N/A

Report date: 2024/05/28 20:00:12
NME

Base Information

Drug NameARV-393
Drug Alias NameARV-393
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionB-cell lymphoma 6 protein degraders
TargetsB-cell lymphoma 6 protein
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesDenmark +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArvinas Operations Inc
China Registration ClassN/A

Develop Information

Active CompaniesArvinas Operations IncArvinas Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A